MedTrace Logo

OCTA and Polypoidal Choroidal Vasculopathy

NCT04714242 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2021-01-19

No results posted yet for this study

Summary

To investigate the structural and vascular features of choroid in patients affected by PCV after Ranibizumab intravitreal injection.

Conditions

  • Polypoidal Choroidal Vasculopathy

Interventions

DRUG

Ranibizumab Injection

Three monthly intravitreal injections of Ranibizumab

Sponsors & Collaborators

  • Federico II University

    lead OTHER

Principal Investigators

  • Gilda Cennamo · Federico II University

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-15
Primary Completion
2020-12-15
Completion
2020-12-20

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04714242 on ClinicalTrials.gov